血清高迁移率族蛋白B1水平对免疫检查点抑制剂肺炎的预测价值
本研究在发现队列87例和验证队列43例非小细胞肺癌患者中,回顾性评估抗PD-1/PD-L1治疗前血清HMGB1水平与3个月内CIP发生的关联。两个队列中CIP患者HMGB1均显著升高,HMGB1高亚组CIP发生率显著高于低亚组,提示HMGB1可能预测CIP发生与严重程度。
要点
- 治疗前血清HMGB1升高与CIP风险增加相关
- HMGB1截断值11.24 ng/ml可区分CIP高发人群
- 19.29 ng/ml截断值可识别5级CIP,敏感性100%
核心结论
- 血清HMGB1可能是预测NSCLC患者CIP发生及严重程度的潜在血液标志物。
研究设计与样本
- 回顾性分析两个大学医院前瞻性储存的抗PD-1/PD-L1单药治疗前血样,发现队列87例、验证队列43例NSCLC患者。
- 评估血清HMGB1水平与开始抗PD-1/PD-L1治疗后3个月内CIP发生的关联。
主要发现
- 发现队列CIP发生9例(10.3%),验证队列6例(14.0%)。
- 两个队列中CIP患者血清HMGB1水平均显著且可重复地更高。
- HMGB1高亚组CIP发生率在发现队列为41.2% vs 2.9%,验证队列为36.4% vs 6.3%。
- 探索性汇总分析中3例死于5级CIP,19.29 ng/ml截断值检测5级CIP敏感性100%、特异性96.85%。
关键数值与推荐
- 发现队列通过ROC分析确定HMGB1截断值为11.24 ng/ml。
- HMGB1高亚组CIP发生率显著高于低亚组:发现队列41.2% vs 2.9%,验证队列36.4% vs 6.3%。
- 19.29 ng/ml HMGB1截断值检测5级CIP敏感性100%、特异性96.85%。
临床怎么用
- 抗PD-1/PD-L1治疗前可考虑检测血清HMGB1以辅助CIP风险分层。
- HMGB1≥11.24 ng/ml的患者可能需要更密切的肺炎监测。
局限性
- 回顾性评估设计。
- 样本量较小(发现队列87例、验证队列43例)。
- 探索性汇总分析中5级CIP事件仅3例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Checkpoint inhibitor pneumonitis (CIP), caused by the anti-programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) antibody, can be a fatal adverse event in cancer patients. However, no predictive biomarkers for CIP have been identified. Because high-mobility group box 1 (HMGB1) can aggravate lung injury and potentially increase the immune response, it was investigated as a predictive blood marker. METHODS: Blood samples, prospectively stored before anti-PD-1/PD-L1 monotherapy between December 2015 and October 2020, were obtained at two university hospitals from 87 and 43 non-small cell lung cancer (NSCLC) patients (discovery and validation cohorts, respectively). We retrospectively evaluated the association of serum HMGB1 levels with the incidence of CIP developed within 3 months of initiating anti-PD-1/PD-L1 therapy. RESULTS: CIP was observed in 9 (10.3%) and 6 (14.0%) patients in the discovery and validation cohorts, respectively. In each cohort, serum HMGB1 levels were significantly and reproducibly higher in patients with CIP. In the discovery cohort, an HMGB1 cut-off level of 11.24 ng/ml was identified by receiver operating characteristic analysis. CIP incidence in the HMGB1high subgroup was significantly higher than that in the HMGB1low subgroup in the discovery (41.2% vs. 2.9%) and validation cohorts (36.4% vs. 6.3%). In an exploratory pooled analysis, three patients died of grade 5 CIP; a 19.29 ng/ml HMGB1 cut-off level detected grade 5 CIP with 100% sensitivity and 96.85% specificity. CONCLUSION: Our results suggest that HMGB1 may be a potential blood marker to predict the development and severity of CIP in NSCLC patients.
引用
- Tanahashi H, Yamaguchi K, Kurose K, et al. Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitis. Respirology. 2022. PMID: 36446578. doi:10.1111/resp.14425
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。